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Background: There are two completely contradictory views regarding the impact of human bone-marrow-derived
mesenchymal stem cells (hMSCs) on hepatocellular carcinomas (HCCs). The aim of this study was to investigate the effect
of hMSC engraftment on HCC tissues in nude mouse models, and assess the effect on metastatic potential of HCC.
Methods: hMSCs were engrafted into the nude mouse models of high metastatic HCC via the tail vein. The mice in the
experimental group were engrafted with hMSCs (5 × 105 cells per mouse) via the tail vein 15 days after inoculation of
tumor cells, twice a week, while the animals in the control group were injected with hMSC culture medium (0.2 mL per
mouse) via the tail vein. The subcutaneous tumor size was measured using an electronic digital caliper once every 4 days
after hMSC engraftment. After 2, 3, 4, 5 and 6 weeks of tumor cell inoculation, the mice were killed and the tumors were
collected in their entirety. The tumor weights and body weights of mice were measured, and the tumor inhibition
rate was calculated. Quantitative real-time polymerase chain reaction (RT-PCR) was used to determine the
expression of metastasis-related genes including osteopontin (OPN), bone sialoprotein (BSP) and integrin α5
subunit (α-V) in the mouse models of high-metastatic HCC, and the expression of apoptosis-related genes
including B cell lymphoma/leukemia-2 (Bcl2), Bcl-2 associated X protein (Bax) and caspase 3 in tumor samples.
Results: The tumor weight inhibition rate was 26.62% at 2 weeks, 52.00% at 3 weeks, 38.20% at 4 weeks, 31.98%
at 5 weeks, and 30.23% at 6 weeks. Tumor tissue weight comparison results were significantly lower in the
hMSC engraftment groups than in the control group at the second and third weeks. The expression of
metastasis-related factors OPN, BSP and α-V gene was downregulated with time. The expression of
antiapoptotic gene Bcl2 exhibited an obvious declining tendency, while the expression of apoptotic genes Bax
and caspase 3 showed an obvious rising tendency. The expression of α-V and BSP significantly correlated
positively with the expression of Bcl2, and negatively correlated with the expression of Bax and caspase 3. The
tumor inhibition rate was not significantly correlated with the expression of antiapoptotic and apoptotic factors,
and α-V and BSP factors, though it exhibited a significantly negative correlation with the expression of OPN.
Conclusions: The highest tumor inhibition rate was observed 3 weeks after hMSCs engraftment, and the tumor
inhibition rate gradually reduced with the progression of time. The metastatic potential of tumor cells was
downregulated after hMSC engraftment and hMSCs induce further tumor cells apoptosis. The decrease in the
proliferation ability of tumor cells may induce a decline in metastatic potential in tumor cells.
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Hepatocellular carcinoma is one of the most common
cancers, with poor prognosis and a high recurrence rate;
metastatic recurrence is the major obstacle to improve
the prognosis of HCC patients. Recently, the biological
treatment of HCC has become a hot research area [1].
Human bone-marrow-derived mesenchymal stem cells
(hMSCs) are a type of adult stem cell with multilineage
differentiation potential. hMSCs are closely associated
with multiple cells in liver tissues, and can differentiate
into oval cells, fibroblasts and myofibroblasts in the liver,
which exhibit functions of repairing injured liver tissues
[2]. Autologous bone-marrow stem-cell transplantation
has been used for treatment of decompensated hepatic
cirrhosis, which proves that stem cell transplantation is
a novel, safe and effective approach [3]. hMSCs exhibit
chemotaxis and homing functions and present a high ef-
ficacy of promoting the reconstruction of the immune
system, removing residual lesions and preventing recur-
rence and metastasis [4]. However, the opposite view
also exists. Researchers believe that hMSCs can promote
the growth and metastasis of hepatocellular carcinoma
cells [5]. In order to investigate intervention effects of
hMSCs with regard to hepatocellular carcinoma tissues,
in the present study hMSCs were engrafted into animal
models of hepatocellular carcinoma (HCC) with high-
metastatic potential. The changes in metastasis potential
were then observed.
Methods
The work for this study was undertaken in the Gynecology
Key Laboratory of Peking University People’s Hospital
from May 2010 to May 2012.
Cell lines
hMSCs were purchased from Cyagen Biosciences
(Guangzhou) Inc. (Guangzhou, China). Human HCC
cells with high metastatic potential (high-metastatic
hepatocellular carcinoma cell 97 (MHCC97-H)) were
supplied by the Liver Cancer Institute of Fudan University
(Shanghai, China).
Experimental animals
A total of 36 6-week-old specific-pathogen-free (SPF)
grade nude mice of the Balb/c strain (female:male ratio
of 1:1), each weighing 14 to 17 g, were purchased from
the Laboratory Animal Center of the National Institutes
for Food and Drug Control (Beijing, China). Animals
were kept within the animal care facility of the Peking
University Health Science Center. The experiments con-
form to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996).
The housing and care procedures in the study wereperformed in accordance with the guidelines and regu-
lations composed by the Animal Care Committee of
the University of Peking University Health Science
Center and approved by the Institutional Animal Care
and Use Committee of the Peking University Health
Science Center, China.
Establishment of nude mouse model of HCC with high
metastatic potential
Normally cultured MHCC97-H cells were prepared into a
single-cell suspension at a concentration of 2 × 105 cells/mL
using a routine technique. Approximately 0.8 mL of the cell
suspension was sampled under aseptic conditions and was
subcutaneously seeded onto the armpit of the upper extrem-
ities of nude mice.
Grouping and intervention methods
Mice were randomly assigned into one of two groups
(n = 15 animals per group), and all mice were weighed
and numbered. The mice in the experimental group
were engrafted with hMSCs (5 × 105 cells per mouse)
via the tail vein 15 days after inoculation of tumor
cells, twice a week for 6 weeks successively, while the
animals in the control group were injected with hMSC
culture medium (0.2 mL per mouse) via the tail vein at
the same time. The subcutaneous tumor size was mea-
sured using an electronic digital caliper once every 4
days after hMSC engraftment. After 2, 3, 4, 5 and 6
weeks of tumor cell inoculation, the mice were killed
and the tumors were collected in their entirety. The
tumor weight and body weight of mice were measured
(see Figure 1).
Data processing method
The tumor inhibition rate was calculated using the fol-
lowing formula:




E(g): mean tumor weight in the experiment group; C(g):
mean tumor weight in the control group.
Determination of expression of osteopontin (OPN), bone
sialoprotein (BSP), integrin α5 subunit (α-V), B cell
lymphoma/leukemia-2 (Bcl2), Bcl-2 associated X protein
(Bax) and caspase 3 in tumor samples from animal models
of high metastatic HCC using quantitative real-time
polymerase chain reaction (RT-PCR)
The primers for RT-PCR amplification were designed
according to the sequences in the GenBank database
(Table 1), which were synthesized by the Cyagen Biosciences
(Guangzhou) Inc. (Guangzhou, China). Human β-actin gene
served as the internal control. Total RNA was isolated from
Tumor bearing nude mice (30)











Figure 1 Experiment design groups and works flow methods. The schematic diagram shows a group situation. Photographs are tumor tissue
specimens in vitro at different timepoints.
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Table 1 Sequences of primers for real-time polymerase
chain reaction (RT-PCR) amplification
Gene Sequence of primer
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using RevertAid™ M-MLV reverse transcriptase and Oligo
(dT). The corresponding cDNA was amplified using a RT-
PCR technique based on specific primers (Table 1), with
predegeneration at 95°C for 5 minutes, followed by
30 cycles of degeneration at 94°C for 30 s, annealing
at 58°C for 30 s, extension at 72°C for 30 s, and the
final elongation at 72°C for 10 minutes. The PCR
amplification product was electrophoresed, and semi-
quantitative analysis of the PCR amplification product
was performed using a gel electrophoresis processing
system.Figure 2 The changes of tumors weight inhibition rate
following engraftment of human mesenchymal stem cells
(hMSCs) over time.Statistical analysis
Tumor inhibition rates were calculated, and a graph of
the tumor inhibition rates change over time was drawn.
The tumor weights were compared between groups at
different timepoints.
All statistical analyses were performed using the SPSS
statistical software version 16.0 (SPSS Inc., Chicago, IL,
USA). The Student t test was used to compare thedifference between groups, with a P value <0.05 indica-
tive of statistical significance.
Results
Effect of hMSCs on transplanted tumors in nude mice
produced by inoculation of MHCC97-H cells
The tumor inhibition rate was calculated according to
the tumor tissue specimen weights in vitro before and
after hMSC intervention. The experimental results show
that the tumor weight inhibition rate was 26.62% at 2
weeks, 52.00% at 3 weeks, 38.20% at 4 weeks, 31.98% at
5 weeks and 30.23% at 6 weeks.
The changes in transplanted tumors in nude mice pro-
duced by inoculation of MHCC97-H cells following en-
graftment of hMSCs for successive 6 weeks are shown in
Figure 2. It was observed that the highest tumor inhib-
ition rate was seen 3 weeks after hMSC engraftment,
and the tumor inhibition rate gradually reduced with
time.
Tumor tissue in vitro weight comparison results were sig-
nificantly lower in the hMSC engraftment groups than in
the control group for the second and third weeks (P <0.01),
but differences were not statistically significant in the
fourth, fifth and sixth weeks between groups (P >0.01)
(Figure 3).
RT-PCR determines the expression of OPN, BSP, α-V, Bcl2,
Bax and caspase 3 genes in animal models of high-
metastatic HCC before and after hMSCs engraftment
Following hMSC engraftment, the expression of metastasis-
related factors OPN, BSP and α-V gene was downregulated
with time. Also, in the fourth week, OPN gene expression in
hMSC engraftment groups was significantly lower than in
control groups (P <0.05). Additionally, in the fourth and fifth
week, BSP gene and α-V gene expression in hMSC engraft-
ment groups was significantly lower than in control groups
(P <0.05). As can be seen from the results, the metastatic
Figure 3 Tumor tissue in vitro weight comparison histogram. (A, B) In the second and third weeks, the tumor weight of human
mesenchymal stem cell (hMSC) engraftment groups was significantly lower than that of control groups (P <0.01). (C, D, E) In the fourth, fifth and
sixth weeks, the difference in tumor weight before and after hMSC intervention was not statistically significant between groups (P >0.01).
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hMSC engraftment, especially in the fourth and fifth
weeks (Figure 4A-C).
Following hMSC engraftment, the expression of
antiapoptotic gene Bcl2 exhibited an obvious declin-
ing tendency, while the expression of apoptotic genes
Bax and caspase 3 showed an obvious rising tendency
(Figure 4D-F). In the fourth and fifth week, Bcl2 gene
expression in hMSC engraftment groups was significantly
lower than in negative (control) groups (P <0.05). Also in
the fourth and fifth week, Bax and caspase 3 gene expres-
sion in hMSC engraftment groups was significantly higher
than in negative (control) groups (P <0.05). As can be seen
from these results, the proliferative ability of tumor cells
decreased and the apoptotic ability of tumor cells in-
creased after hMSC engraftment.The results show that the metastatic potential of tumor
cells was downregulated after hMSC engraftment, and
hMSCs induced more tumor cells apoptosis.
Correlation analysis between metastasis-related factor
expression and apoptotic gene expression in animal
models inoculated with MHCC97-H cells after hMSCs
engraftment
The expression of metastasis-related factor α-V was sig-
nificantly positively correlated with the expression of
antiapoptotic factor Bcl2 (r = 0.908, P <0.01), and nega-
tively correlated with the expression of apoptotic factors
Bax (r = −0.803, P <0.01) and caspase 3 (r = −0.902, P <0.01).
The expression of metastasis-related factor BSP was sig-
nificantly positively correlated with the expression of
antiapoptotic factor Bcl2 (r = 0.890, P <0.01), and negatively
Figure 4 Gene expression in animal models inoculated with high-metastatic hepatocellular carcinoma cell 97 (MHCC97-H) cells before
and after human mesenchymal stem cell (hMSC) engraftment. (A) The expression of metastasis-related factor osteopontin (OPN) by the
tumor tissue specimen over time. (B) The expression of metastasis-related factor bone sialoprotein (BSP) by the tumor tissue specimen over time.
(C) The expression of metastasis-related factor integrin α5 subunit (α-V) by the tumor tissue specimen over time. (D) The expression of
antiapoptotic gene B cell lymphoma/leukemia-2 (Bcl2) by the tumor tissue specimen over time (note: negative is the control group). (E, F) The
expression of apoptotic gene Bcl-2 associated X protein (Bax) and caspase 3 by the tumor tissue specimen over time (note: negative is the
control group).
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Bax (r = −0.779, P <0.05) and caspase 3 (r = −0.910,
P <0.01).
The expression of metastasis-related factor OPN was
not significantly correlated with the expression of
antiapoptotic factor Bcl2 (r = 0.553, P >0.05), and was
negatively correlated with the expression of apoptotic factors
Bax (r = −0.368, P >0.05) and caspase 3 (r = −0.586, P >0.05)
(Figure 5).
The results suggested that the decrease of proliferation
ability of tumor cells can induce the decline of meta-
static potential of tumor cells.
Correlation analysis between apoptotic and metastasis-
related gene expression and tumor inhibition rate in
animal models inoculated with MHCC97-H cells after
hMSC engraftment
The tumor inhibition rate was not significantly correlated
with the expression of antiapoptotic factor Bcl2 (r = −0.095,P >0.05), and apoptotic factors Bax (r = −0.087, P >0.05)
and caspase 3 (r = 0.144, P >0.05).
The tumor inhibition rate was not significantly corre-
lated with the expression of metastasis-related factors α-V
(r = −0.411, P >0.05) and BSP (r = −0.521, P >0.05) factors,
but it exhibited a significant negative correlation with the
expression of metastasis-related factor OPN (r = −0.766,
P <0.05) (Figure 6).
These results suggest that the changes in tumor apop-
totic or antiapoptotic genes were not the main factors
affecting the tumor inhibition rate. Also, the changes in
tumor inhibition rate were not the main factors affecting
the metastatic potential of tumor cells.
Discussion
Liver cancer is one of the most common malignant tu-
mors, and it is the second most common cause of death
from cancer in China. Currently, surgical resection re-
mains the most effective approach for treatment of the
Figure 5 Correlation analysis (trend charts) between
metastasis-related factor expression and apoptotic factor
expression in animal models inoculated with high-metastatic
hepatocellular carcinoma cell 97 (MHCC97-H) cells after human
mesenchymal stem cell (hMSC) engraftment. (A) Correlation
between metastasis-related factor integrin α5 subunit (α-V) and
antiapoptotic factor B cell lymphoma/leukemia-2 (Bcl2), and
apoptotic factors Bcl-2 associated X protein (Bax) and caspase 3.
(B) Correlation between metastasis-related factor bone sialoprotein
(BSP), and antiapoptotic factor Bcl2 and apoptotic factors Bax and
caspase 3. (C) Correlation between metastasis-related factor
osteopontin (OPN) and antiapoptotic factor Bcl2, and apoptotic
factors Bax and caspase 3.
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dence of post-surgical recurrence and metastasis. An es-
timated 40% to 50% 5-year recurrence rate after surgery
is observed in small liver cancers, which is widely recog-
nized to have a good prognosis in clinical practice [6].
Therefore, post-surgical early recurrence and metastasis
has become critical as the main hindrance to the long-
term survival of patients with liver cancer [6]. It has
been found that bone-marrow-derived stem cells are a
major extrahepatic source of hepatic stem cells, and
bone-marrow-derived stem cells engrafted into the liver
tissues of patients can differentiate into liver tissues and
stem cells under a specific environment, thereby becom-
ing involving in liver repair and reconstruction [2,3,7].
Autologous bone-marrow-derived stem cells have been
engrafted into the injured liver for treatment of decom-
pensated hepatic cirrhosis, which proves that stem cell
transplantation is a novel, safe and effective treatment
method [8,9]. Stem cell therapy has chemotaxis and
homing functions in the treatment of liver cancer, and it
presents a high efficacy for promoting the reconstruction
of the immune system, removing residual lesions, and
preventing recurrence and metastasis [10]. However,
there are two completely contradictory views concerning
the impact of human bone-marrow-derived mesenchy-
mal stem cells (hMSCs) on hepatocellular carcinomas
(HCCs). Some researchers believe that MSCs are a
source of circulating progenitors that are able to generate
cells of all mesenchymal lineages and cover the cellular
demands of injured tissues. MSCs present immunosup-
pressive and anti-inflammatory features and a high migra-
tory capacity toward inflamed or remodeling tissues.
Moreover, experimental evidence has been shown that
supports the use of MSCs as a tool in liver fibrosis and he-
patocellular carcinoma [4]. However, other researchers
hypothesize that MSCs enhance tumor growth but signifi-
cantly inhibit the invasiveness and metastasis of HCC
[11]. Simulation of human tumors in live systems and es-
tablishment of tumor models for basic research is a com-
mon method in medical research [12]. In mouse models,
stem cell transplantation inhibits post-surgical recurrence
Figure 6 Correlation analysis (trend charts) between apoptotic
and metastasis-related genes expression and tumor inhibition
rate in animal models inoculated with high-metastatic
hepatocellular carcinoma cell 97 (MHCC97-H) cells after human
mesenchymal stem cell (hMSC) engraftment. (A) Correlation
between antiapoptotic factor B cell lymphoma/leukemia-2 (Bcl2),
and apoptotic factors Bcl-2 associated X protein (Bax) and caspase 3
gene expression and the tumor inhibition rate in animal models.
(B) Correlation between metastasis-related gene expression and the
tumor inhibition rate in animal models.
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the antitumor activity is enhanced with the increased chi-
merism level of hMSC [7].
hMSCs at passages 5 to 8 were used in the present
study. Phenotypic identification indicated that the hMSCs
at passages 5 to 8 used in this study had all characteristics
of hMSCs, which met the requirements for the experi-
ments. Establishment of tumor animal models is a com-
mon experimental technique in clinical practice [6]. This
study established nude mouse models of HCC with high
metastatic potential through inoculation of tumor cells
(MHCC97-H cell), and hMSCs were engrafted via the tail
vein for intervention treatment of HCC by means of thehoming function of hMSCs, so as to observe the thera-
peutic efficacy of hMSCs against HCC and the effect on
high metastatic potential.
The experimental results showed that the hMSCs had
an inhibitory effect on HCC in animal models, but the
effectiveness of the intervention of hMSCs changed with
time. The highest tumor inhibition rate was observed at
3 weeks after hMSC engraftment, and the inhibitory
efficiency of hMSCs reduced with time. This demon-
strates that hMSCs exhibit antitumor activity in a
time-dependent manner.
With regard to the intervention mechanism of hMSCs
on liver cancer, studies have reported that hMSCs are
found to colonize the liver of mouse models of orthotopic
liver transplantation, and can differentiate into hepato-
cytes that express albumin; in addition, the hMSCs are
mainly found in the marginal area of the tumor and rarely
present in tumors or normal liver tissues, and a large nec-
rotic area is observed in tumor tissues following hMSC
transplantation [12]. In addition to homogeneous gene
characteristics and multilineage differentiation potential,
hMSCs also have a high efficacy of immunosuppression
and anti-infection activity, and the characteristics of mi-
gration to inflammatory tissues and remodeling tissues
(homing characteristic), which accelerate the repair of in-
jured liver tissues, inhibit immune responses and confer
antihepatic fibrosis functions [4]. However, prior to this
work, to the best of our knowledge there have been no re-
ports on hMSC antitumor activity in a time-dependent
manner.
To further validate the inhibitory effect of hMSCs on
HCC, the expression of some apoptosis-associated fac-
tors was determined. The Bcl2 family plays a critical role
in apoptosis. The Bcl2 family members are classified into
two types: antiapoptotic factors, which mainly include
Bcl2, Bcl-XL, Bcl-W, Mcl-1 and CED9, and proapoptotic
factors, which mainly include Bax, Bak, Bcl-XS, Bad, Bik
and Bid. The caspase family plays a very important role
in mediating apoptosis, where caspase 3 is a key effector
and functions in many apoptosis signaling transduction
pathways [13]. From the experimental results, we can
draw the conclusion that hMSCs induce greater tumor
cells apoptosis, and also, similar to the tumor inhibition
rate experiment results, the apoptosis-associated factor
test results also show a time-dependent effect, but the
timepoints are different. Therefore, the correlation ana-
lysis results suggest that the changes in tumor apoptotic
or antiapoptotic genes were not the main factors affect-
ing the tumor inhibition rate. Thus, the mechanism of
the time-dependent manner of hMSC antitumor activity
requires further investigation.
The study determined the expression of metastasis-
related factors to observe the effect of hMSCs on meta-
static potential of HCC. The results show that the
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after hMSC engraftment. Additionally, the tumor in-
hibition rate was not significantly correlated with the
expression of metastasis-related factors, and the posi-
tive correlation with OPN may be due to experimen-
tal error. However, the correlation analysis between
metastasis-related and apoptosis-associated factor re-
sults suggest that the decrease in proliferation ability
of tumor cells can induce the decline in metastatic
potential of tumor cells. Regardless, the present study
also has some shortcomings. The method for deter-
mination of tumor metastatic potential in animal
models is excessively dependent on molecular bio-
logical indexes, while the detection of traditional
morphology is neglected.
The present study demonstrates the role of hMSCs in
growth and metastasis of HCC tissues through injection
of hMSCs via the tail vein, which provides new insight
into exploring the relationship between hMSCs and liver
cancer metastasis, and may provide a new cytological
method for clinical treatment of liver cancer metastasis.
It is of great significance to be able to effectively control
the pro-proliferative effect and exert the metastatic in-
hibition ability of hMSCs.
Conclusions
The highest tumor inhibition rate was observed 3 weeks
after hMSC engraftment, and the tumor inhibition rate
gradually reduced with time. The metastatic potential of
tumor cells was downregulated after hMSC engraftment
and hMSCs promoted apoptosis of tumor cells. The de-
crease in proliferation ability of tumor cells can induce a
decline in the metastatic potential of tumor cells. The
changes in tumor apoptotic or antiapoptotic genes were
not the main factors affecting the tumor inhibition rate.
Also, the changes in tumor inhibition rate were not the
main factors affecting the metastatic potential of tumor
cells.
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